New pill shows promise for Hard-to-Treat cancers

NCT ID NCT06558513

Completed Disease control Sponsor: Evopoint Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called XNW5004 in 120 people with advanced tumors or lymphoma that had come back or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it helps shrink tumors. The drug is taken as a tablet twice a day.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XNW5004 tablets (an EZH2 inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for patients with advanced tumors or lymphoma who have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not prove effective or safe in larger studies. Side effects are possible and being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer follicular lymphoma lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TUMOR LYMPHOMA

Contacts and locations

Locations

Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.